PBMs

COMMENTARY

Oncology patients at serious risk with Congress’ drug pricing plan

BY: - August 5, 2022

As Congress works to lower health care costs, we reach a critical point in our nation’s debate over what consumers must pay for prescription medicines. The current Senate budget reconciliation package is hyper-focused on bringing down drug prices. Unfortunately, the legislation is short-sighted, and ignores a key remedy that would help lower out-of-pocket costs for […]

COMMENTARY

Dangerous care delays ahead if more insurers implement “white bagging” policies

BY: - December 15, 2021

Consider the following scenario: A cancer patient comes into a community oncology clinic for their regularly scheduled chemotherapy treatment. After concluding the pre-treatment evaluation, the oncologist determines that the patient’s dose should be adjusted. Perhaps they need a higher dose than what we previously administered — a fairly common occurrence in the world of cancer […]

Pharmacy middlemen sue to stop rebate transparency

BY: - August 20, 2021

An industry group representing powerful drug middlemen has gone to court to stop a federal rule intended to bring transparency to rebates middlemen get from manufacturers. The middlemen are arguing that the rule, initiated by the Trump administration, will increase drug costs. But the group’s critics say that secretive rebates are a primary driver of […]

COMMENTARY

2+2=? Senate uses murky math as it shelves drug pricing rule to fund infrastructure

BY: - August 6, 2021

By Michael McAuliff, Kaiser Health News The Senate’s release of its bipartisan infrastructure plan signals that lawmakers are poised to throw former President Donald Trump’s belated bid to lower Medicare drug prices under the bus — not to mention trains, bridges, tunnels and broadband connections. That’s because the massive spending bill is the first of […]

COMMENTARY

To fix drug costs, stop Big Pharma price-gouging and tax-dodging

BY: - May 27, 2021

By Hannah Hendrix, American Medical Student Association I’m studying at The Ohio State University to become a doctor because I want to help people. Unfortunately, far too many Americans today are confronting skyrocketing prescription drug costs that prevent them from following their doctor’s advice because they can’t afford treatments they need. Drug prices are rising […]

Drugmaker on rising prices: Don’t look at us

BY: - April 27, 2021

A subsidiary of a leading U.S. drugmaker is reporting that the net cost of its products has been falling. If that’s true, it would appear that drug middlemen and insurers are driving increases in the overall cost of medicine and in consumers’ out-of-pocket costs at the counter. The report, by Johnson & Johnson subsidiary Janssen […]

U.S. Supreme Court deals big blow to pharmacy middlemen

BY: - December 10, 2020

The U.S. Supreme Court on Thursday ruled 8-0 that states have broad powers to regulate powerful pharmacy middlemen without being preempted by federal law. The case was brought by the $400-billion-a-year industry, known as “pharmacy benefit managers,” against the state of Arkansas over a 2015 law that set a minimum, market-based rate the middlemen had […]

Feds said to be investigating largest Medicaid provider in the U.S.

BY: - July 20, 2020

Federal officials are probing actions taken in Ohio in 2017 by the largest Medicaid managed care provider in the United States, a source familiar with the investigation has told Ohio Capital Journal.  The U.S. Centers for Medicaid and Medicare Services declined to confirm or deny the existence of an investigation. But the source said the […]